双特异性抗体用于淋巴细胞恶性瘤治疗
Matteo Bisio1, Luca Legato1, Filippo Fasano1
1Hematology Division, A.O.U. Città della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy.
Cancers
|January 11, 2025
概括
双特异性抗体 (BsAbs) 为复发性/耐药性B细胞非霍奇金淋巴瘤提供了一个有前途的新疗法. 这些现成的疗法在重度预治疗的患者中显示出显著的活性和可控的安全性.
科学领域:
- 血液学 血液学 血液学
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
背景情况:
- 在过去的20年里,免疫疗法彻底改变了B细胞非霍奇金淋巴瘤 (B-NHLs) 的治疗方法.
- 进展包括CAR-T疗法,抗体-药物合物和双特异性抗体 (BsAbs).
- 这些疗法对于治疗扩散性大B细胞淋巴瘤 (DLBCL),毛囊淋巴瘤 (FL) 和地幔细胞淋巴瘤 (MCL) 至关重要.
研究的目的:
- 审查最近和正在进行的双特异性抗体 (BsAb) 试验,用于复发/耐药 (R/R) B-NHL和霍奇金淋巴瘤.
- 要总结单剂结果,组合疗法,安全数据和新型BsAb构造.
- 提供BsAb在淋巴瘤治疗中的有效性和安全性的最新概述.
主要方法:
- 对涉及双特异抗体 (BsAbs) 的已完成和正在进行的临床试验的审查.
- 对单剂BsAb治疗的已发表数据的分析.
- 评估涉及BsAbs. 的新兴组合策略.
- 评估来自BsAb试验的安全性概况和毒性数据.
主要成果:
- 双特异性抗体 (BsAbs) 在严重预处理的B-NHL中表现出显著的单剂活性.
- 新兴的BsAbs组合显示出增强治疗效果的潜力.
- 新的BsAb结构针对CD19 × CD3和CD30 × CD3等抗原正在调查中.
- 在R/R B-NHL.患者中,BsAbs表现出可管理的毒性特征.
结论:
- 双特异性抗体 (BsAbs) 是一种新的"现成"T细胞重定向疗法.
- 对于淋巴瘤患者来说,BsAbs是一种非常有前途的治疗选择,特别是那些患有R/R B-NHL的患者.
- 目前正在进行的研究正在探索新的抗原标和组合,以进一步优化BsAb疗法.
相关概念视频
01:27Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
01:20Special Features of Adaptive Immunity
744
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
744